Complement C3f serum levels may predict breast cancer risk in women with gross cystic disease of the breast

Journal of Proteomics

Volumn 85, Issue , 2013, Pages 44-52

  Profumo, Aldo ^a   Mangerini, Rosa ^a   Rubagotti, Alessandra ^a,b   Romano, Paolo ^a   Damonte, Gianluca ^b   Guglielmini, Pamela ^b   Facchiano, Angelo ^c   Ferri, Fabio ^d   Ricci, Francesco ^b   Rocco, Mattia ^a   Boccardo, Francesco ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Breast cancer risk; Complement C3f; MALDI TOF; Peptidome profile; Serum

Indexed keywords

COMPLEMENT C3F; COMPLEMENT COMPONENT C3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CYST; CANCER RISK; COMPLEMENT ACTIVATION; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; CRYOPRESERVATION; FEMALE; HUMAN; ION TRAP MASS SPECTROMETRY; MAJOR CLINICAL STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PREDICTIVE VALUE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ADULT; BREAST NEOPLASMS; COMPLEMENT ACTIVATION; COMPLEMENT C3B; FEMALE; FIBROCYSTIC BREAST DISEASE; HUMANS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84878184497     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.04.029     Document Type: Article

References (30)

1. Dixon J.M., McDonald C., Elton R.A., Miller W.R. Risk of breast cancer in women with palpable breast cysts: a prospective study Edinburgh Breast Group. Lancet 1999, 353:1742-1745.
2. Haagensen D.E. Is cystic disease related to breast cancer?. Am J Surg Pathol 1991, 15:687-694.
3. Boccardo F., Valenti G., Zanardi S., Cerruti G., Fassio T., Bruzzi P., et al. Epidermal growth factor in breast cyst fluid: relationship with intracystic cation and androgen conjugate content. Cancer Res 1988, 48:5860-5863.
4. Boccardo F., Torrisi R., Zanardi S., Valenti G., Pensa F., De Franchis V., et al. EGF in breast cyst fluid: relationships with intracystic androgens, estradiol and progesterone. Int J Cancer 1991, 47:523-526.
5. Boccardo F., Marenghi C., Ghione G., Pepe A., Parodi S., Rubagotti A. Intracystic epidermal growth factor level is predictive of breast-cancer risk in women with gross cystic disease of the breast. Int J Cancer 2001, 95:260-265.
6. Celis J.E., Gromov P., Moreira J.M., Cabezón T., Friis E., Vejborg I.M., et al. Apocrine cysts of the breast: biomarkers, origin, enlargement, and relation with cancer phenotype. Mol Cell Proteomics 2006, 5:462-483.
7. Alexander H., Stegner A.L., Wagner-Mann C., Du Bois G.C., Alexander S., Sauter E.R. Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. Clin Cancer Res 2004, 10:7500-7510.
8. Pavlou M.P., Kulasingam V., Sauter E.R., Kliethermes B., Diamandis E.P. Nipple aspirate fluid proteome of healthy females and patients with breast cancer. Clin Chem 2010, 56:848-855.
9. Rui Z., Jian-Guo J., Yuan-Peng T., Hai P., Bing-Gen R. Use of serological proteomic methods to find biomarkers associated with breast cancer. Proteomics 2003, 3:433-439.
10. Li J., Zhang Z., Rosenzweig J., Wang Y.Y., Chan D.W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002, 48:1296-1304.
11. Gast M.C., Zapatka M., van Tinteren H., Bontenbal M., Span P.N., Tjan-Heijnen V.C., et al. Postoperative serum proteomic profiles may predict recurrence-free survival in high-risk primary breast cancer. J Cancer Res Clin Oncol 2011, 137:1773-1783.
12. Villanueva J., Shaffer D.R., Philip J., Chaparro C.A., Erdjument-Bromage H., Olshen A.B., et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006, 116:271-284.
13. Opstal-van Winden A.W., Krop E.J., Kåredal M.H., Gast M.C., Lindh C.H., Jeppsson M.C., et al. Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study. BMC Cancer 2011, 11:381.
14. Mangerini R., Romano P., Facchiano A., Damonte G., Muselli M., Rocco M., et al. The application of atmospheric pressure matrix-assisted laser desorption/ionization to the analysis of long-term cryopreserved serum peptidome. Anal Biochem 2011, 417:174-181.
15. Romano P., Profumo A., Mangerini R., Ferri F., Rocco M., Boccardo F., et al. Geena, a tool for MS spectra filtering, averaging and aligning. EMBnet J 2012, 18(Suppl. A):125-126.
16. Efron B. Bootstrap methods: another look at the jackknife. Ann Stat 1979, 7:1-26.
17. Efron B., Tibshirani R. An introduction to the bootstrap 1993, Chapman & Hall/CRC, Boca Raton.
18. Timms J.F., Cramer R., Camuzeaux S., Tiss A., Smith C., Burford B., et al. Peptides generated ex vivo from serum proteins by tumor-specific exopeptidases are not useful biomarkers in ovarian cancer. Clin Chem 2010, 56:262-271.
19. Yi J., Liu Z., Craft D., O'Mullan P., Ju G., Gelfand C.A. Intrinsic peptidase activity causes a sequential multi-step reaction (SMSR) in digestion of human plasma peptides. J Proteome Res 2008, 7:5112-5118.
20. O'Mullan P., Craft D., Yi J., Gelfand C.A. Thrombin induces broad spectrum proteolysis in human serum samples. Clin Chem Lab Med 2009, 47:685-693.
21. Nishimura H., Kakizaki I., Muta T., Sasaki N., Pu P.X., Yamashita T., et al. cDNA and deduced amino acid sequence of human PK-120, a plasma kallikrein-sensitive glycoprotein. FEBS Lett 1995, 357:207-211.
22. van Winden A.W., van den Broek I., Gast M.C., Engwegen J.Y., Sparidans R.W., van Dulken E.J., et al. Serum degradome markers for the detection of breast cancer. J Proteome Res 2010, 9:3781-3788.
23. Ishida Y., Yamashita K., Sasaki H., Takajou I., Kubuki Y., Morishita K., et al. Activation of complement system in adult T-cell leukemia occurs mainly through lectin pathway: a serum proteomic approach using mass spectrometry. Cancer Lett 2008, 271:167-177.
24. Villanueva J., Martorella A.J., Lawlor K., Philip J., Fleisher M., Robbins R.J., et al. Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol Cell Proteomics 2006, 5:1840-1852.
25. Janssen B., Huizinga E.G., Raaijmakers H.C., Roos A., Daha M.R., Nilsson-Ekdahl K., et al. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 2005, 437:505-511.
26. Niculescu F., Rus H.G., Retegan M., Vlaicu R. Persistent complement activation on tumor cells in breast cancer. Am J Pathol 1992, 140:1039-1043.
27. Dunn G.P., Old L.J., Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21:137-148.
28. Chang J., Chen L.C., Wei S.Y., Chen Y.J., Wang H.M., Liao C.T., et al. Increase diagnostic efficacy by combined use of fingerprint markers in mass spectrometry-plasma peptidomes from nasopharyngeal cancer patients for example. Clin Biochem 2006, 39:1144-1151.
29. Kabbage M., Chahed K., Hamrita B., Lemaitre-Guillier C., Trimeche M., Remadi S., et al. Protein alterations in infiltrating ductal carcinomas of the breast as detected by nonequilibrium pH gradient electrophoresis and mass spectrometry. J Biomed Biotechnol 2008, 2008:564127. http://dx.doi.org/10.1155/2008/564127.
30. Umemura H., Togawa A., Sogawa K., Satoh M., Mogushi K., Nishimura M., et al. Identification of a high molecular weight kininogen fragment as a marker for early gastric cancer by serum proteome analysis. J Gastroenterol 2011, 46:577-585.